In addition, immunohistochemical results of tumor tissues provided strong molecular evidence to support the prediction of network pharmacology that PSP can mediate tumor growth by inhibiting the JAK2-STAT3 signaling pathway. This evidence concerns the gene JAK2 and neoplasm.